We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mission Therapeutics inks a collaboration agreement with AbbVie aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease.